A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Bakri, Syakib
- A Comparative Study of Early Response Rate between Patient Given Standard Chemotherapy with Patient Given Combination Targeted Therapy in Non-Hodgkin Lymphoma Patients
Authors
1 Hasanuddin University, Makassar, South Sulawesi, ID
2 Medical Hematology and Oncology Division of Internal Medicine Department, Hasanuddin University, Makassar, South Sulawesi, ID
Source
Indian Journal of Public Health Research & Development, Vol 10, No 11 (2019), Pagination: 1793-1797Abstract
Background: Treatment for non-Hodgin Lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen. Rituximab in combination with CHOP (RCHOP) increases better response rate without any significant increase in toxicity. The standard definition of treatment responseis based on changes in lesion dimensions with time. We conducted a comparative study to compare early response rate between CHOP andCHOP in NHL patients.
Method: This study was using cohort prospective analysis and conducted at Wahidin Sudirohusodo Hospital from September 2018 until June 2019. The response rate was measured with the longest diameter of tumor and compared after 2 observational cycle periods of chemotherapy. Analysis to compare responserate was carried out using Independent T-test analysis.
Results: Seventy patients enroll this study consisting of 38 subjects in CHOP group and 32 subjects in RCHOP group. Analysis to compare early responserate between CHOP and RCHOP was significant with p-value 0.001 (46.6% vs 67.0%;).
Conclusions: Early response rate in patient given combination targeted therapy have better response rate than patient given standard regiment chemotherapy.
Keywords
Early ResponseRate, RCHOP, CHOP, Non-Hodgkin Lymphoma.- A Three-Years Survival Rates of Chronic Myeloid Leukemia Patients with Targeted Therapy
Authors
1 Internal Medicine Department, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, ID
2 Hematology and Oncology Division of Internal Medicine Department, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, ID
Source
Indian Journal of Public Health Research & Development, Vol 11, No 1 (2020), Pagination: 1436-1449Abstract
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCRABL fusion protein that arises from the translocation of chromosomes 9 and 22. Since the found of the Tyrosine Kinase Inhibitor (TKI) as a targeted therapy, the relative survival rate of 5 years has significantly increased compared to the era of the use of previous agents. As a successful leukemia treatment, it can be seen based on the survival rate. Several factors have been known to influence the survival and prognosis of CML patients, including the age of the patient at diagnosis, gender, and response to therapy and treatment. This study aims to determine how many a three-year survival rates for CML patients with targeted therapy in Makassar and the factors that affect survival.
Method: This study used a retrospective cohort using secondary data (medical records) of CML subjects who had been outpatient or inpatient followed in the same time period. The study was conducted in January 2015 to December 2017 at Dr. Wahidin Sudirohusodo Hospital, Makassar. The samples consisted of 108 subjects who met the inclusion criteria. Gender, age, BCR-ABL transcript, targeted therapy and status were taken from medical records. Data were analyzed with SPSS 22.0 version and survival analysis, Meier Kapplan curves, survival median, log-rank and test statistic.
Results: There were 108 subjects of CML patients who received targeted therapy, 58 male (53.7%), 30-39 years old 32 subjects (29.6%), b3a2 transcript 67 subjects (73.6%), Imanitib 62 subjects (57.4%) and status for 36 months was followed during the targeted treatment of dead 19 subjects (17.6%) and alive 89 (82.4%). The survival rate of a three years CML subjects who received targeted therapy of 51%, found no significant relationship between gender, age, and targeted therapy.
Conclusion: The survival rate of three years of CML patients at Wahidin Sudirohusodo Makassar Hospital is 51% and factors related to age, gender, and targeted therapy tend to influence even though statistically not significant,
Keywords
Three-Year Survival, CML, Targeted Therapy.- A Three-Years Survival Rates of Chronic Myeloid Leukemia Patients with Targeted Therapy
Authors
1 Hasanuddin University, Makassar, South Sulawesi, ID
Source
Indian Journal of Public Health Research & Development, Vol 11, No 2 (2020), Pagination: 1814-1819Abstract
Background:Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22. Since the found of the Tyrosine Kinase Inhibitor (TKI) as a targeted therapy, the relative survival rate of 5 years has significantly increased compared to the era of the use of previous agents. As a successful leukemia treatment, it can be seen based on the survival rate. Several factors have been known to influence the survival and prognosis of CML patients, including the age of the patient at diagnosis, gender, and response to therapy and treatment. This study aims to determine how many a three-year survival rates for CML patients with targeted therapy in Makassar and the factors that affect survival.
Method:This study used a retrospective cohort using secondary data (medical records) of CML subjects who had been outpatient or inpatient followed in the same time period. The study was conducted in January 2015 to December 2017 at Dr. Wahidin Sudirohusodo Hospital, Makassar. The samples consisted of 108 subjects who met the inclusion criteria. Gender, age, BCR-ABL transcript, targeted therapy and status were taken from medical records. Data were analyzed with SPSS 22.0 version and survival analysis, Meier Kapplan curves, survival median, log-rank and test statistic
Results:There were 108 subjects of CML patients who received targeted therapy, 58 male (53.7%), 30-39 years old 32 subjects (29.6%), b3a2 transcript 67 subjects (73.6%), Imanitib 62 subjects (57.4%) and status for 36 months was followed during the targeted treatment of dead 19 subjects (17.6%) and alive 89 (82.4%). The survival rate of a three years CML subjects who received targeted therapy of 51%, found no significant relationship between gender, age, and targeted therapy
Conclusion:The survival rate of three years of CML patients at Wahidin Sudirohusodo Makassar Hospital is 51% and factors related to age, gender, and targeted therapy tend to influence even though statistically not significant.